{"id":"NCT03189745","sponsor":"Pfizer","briefTitle":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","officialTitle":"A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-01","primaryCompletion":"2018-04-11","completion":"2018-04-11","firstPosted":"2017-06-16","resultsPosted":"2020-10-12","lastUpdate":"2020-10-12"},"enrollment":229,"design":{"allocation":"NA","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal ACWY Disease"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-TT","otherNames":[]}],"arms":[{"label":"MenACWY-TT Booster","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix) or Mencevax ACWY","primaryOutcome":{"measure":"Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination","timeFrame":"1 month after booster vaccination","effectByArm":[{"arm":"ACWY-TT Group","deltaMin":81.5,"sd":null},{"arm":"MenPS Group","deltaMin":84.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=MENACWY-TT-101"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":170},"commonTop":["Injection site pain (pain at injection site)","Fatigue","Gastrointestinal","Injection site erythema (redness)","Injection site swelling (swelling)"]}}